EUVIMEDEUVIMED entdecken
Crossref

The lymphocyte-thrombocyte-CRP (LTC) score as a pre-therapeutic prognostic marker in patients with head and neck cancer (HNC)

Michael Peis, Vinithagowry Sivakumar, Lukas Boosfeld, Sebastian Waßenberg, Stefan Mattheis, Jadwiga Jablonska, Stephan Lang, Timon Hussain, Cornelius Kürten

Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S212

DOI: 10.1055/s-0044-1784689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Michael Peis und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Systemic inflammation, measured for example as neutrophil-lymphocyte ratio (NLR) or systemic inflammatory index (SII), is associated with a negative influence on survival in patients with HNC. These indices require laboratory analyses and mathematical calculations. This study examines a simple three-point scoring system based on lymphocyte-, thrombocyte- and CRP levels has prognostic significance.

Methods

The pre-therapeutic laboratory data of 994 patients was collected by retrospective chart review. Patients with elevated levels of lymphocytes, thrombocytes or CRP received one point for each pathologically elevated laboratory result (range 0 – 3). Using SPSS (version 29 for MAC), we analysed and visualized overall and relapsing-free survival using Kaplan-Meier curves and the log rank test.

Results

375 (43.0%) patients had a score of 0, 310 (35.5%) patients had a score of 1, 142 (16.3%) patients had a score of 2, and 45 (5.2%) patients had a score of 3. The Kaplan Meier analysis showed a significantly longer overall survival with an LCT score of 0 compared to patients with an increased values (median survival 100 months for a score of 0, 53 months for a score of 1, 25 months for a score of 2 and 12 months for score of 3). A similar relationship can be demonstrated for relapse-free survival (median survival 110 months for a score of 0, 77 months for a score of 1, 70 months for a score of 2 and 33 months for a score of 3).

Conclusion

The LTC score can be used as a pre-therapeutic prognostic marker with regard to overall survival, as well as relapse-free survival, in patients with HNC. In the future, a multivariate comparison will be performed, which includes other prognostic markers, such as tumour stage and p16 status, as well as the NLR and the SSI. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Peis, M., Sivakumar, V., Boosfeld, L., Waßenberg, S., Mattheis, S., Jablonska, J., Lang, S., Hussain, T., & Kürten, C. (2024). The lymphocyte-thrombocyte-CRP (LTC) score as a pre-therapeutic prognostic marker in patients with head and neck cancer (HNC). Laryngo-Rhino-Otologie, 103(S 02 S 02), S212. https://doi.org/10.1055/s-0044-1784689

Vancouver

Peis M, Sivakumar V, Boosfeld L, Waßenberg S, Mattheis S, Jablonska J, et al. The lymphocyte-thrombocyte-CRP (LTC) score as a pre-therapeutic prognostic marker in patients with head and neck cancer (HNC). Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S212. doi:10.1055/s-0044-1784689

BibTeX
@article{Peis2024,
  author = {Peis, Michael and Sivakumar, Vinithagowry and Boosfeld, Lukas and Waßenberg, Sebastian and Mattheis, Stefan and Jablonska, Jadwiga and Lang, Stephan and Hussain, Timon and Kürten, Cornelius},
  title = {The lymphocyte-thrombocyte-CRP (LTC) score as a pre-therapeutic prognostic marker in patients with head and neck cancer (HNC)},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S212},
  doi = {10.1055/s-0044-1784689}
}
Kostenlos starten →